ALNY insider transactions
Alnylam Pharmaceuticals Inc. (ALNY) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for ALNY
- Director Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 4 filed by Director Cravatt Benjamin4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 3 filed by new insider Cravatt Benjamin3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Sigal Charles Elliott was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Schulman Amy W was granted 838 shares, increasing direct ownership by 4% to 24,049 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Reitan Colleen F was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Pyott David E I was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Kellogg Peter N was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Hamburg Margaret A was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Brandicourt Olivier was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Ausiello Dennis A was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Arbuckle Stuart A was granted 671 shares (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Schulman Amy W exercised 11,250 shares at a strike of $70.20, increasing direct ownership by 94% to 23,211 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 4 filed by Mclaughlin Melissa4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 3 filed by new insider Mclaughlin Melissa3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal sold $1,524,796 worth of shares (4,713 units at $323.53), decreasing direct ownership by 20% to 18,693 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne sold $947,581 worth of shares (2,933 units at $323.08), decreasing direct ownership by 3% to 95,695 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. sold $797,351 worth of shares (2,468 units at $323.08), decreasing direct ownership by 4% to 61,805 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga sold $745,984 worth of shares (2,309 units at $323.08), decreasing direct ownership by 6% to 34,297 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold $417,685 worth of shares (1,291 units at $323.54), decreasing direct ownership by 6% to 20,569 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. was granted 4,769 shares and sold $722,801 worth of shares (2,206 units at $327.65), increasing direct ownership by 4% to 64,273 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal was granted 4,769 shares and sold $1,130,131 worth of shares (3,492 units at $323.63), increasing direct ownership by 6% to 23,406 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 3,688 shares and sold $1,051,773 worth of shares (3,250 units at $323.62), increasing direct ownership by 2% to 21,860 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga was granted 4,769 shares and sold $523,584 worth of shares (1,598 units at $327.65), increasing direct ownership by 9% to 36,606 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, CLO and Secretary Supran Bryan was granted 1,539 shares, increasing direct ownership by 12% to 14,565 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne was granted 13,844 shares and sold $2,227,698 worth of shares (6,799 units at $327.65), increasing direct ownership by 8% to 98,628 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne converted options into 5,921 shares, increasing direct ownership by 7% to 91,583 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal converted options into 1,908 shares and sold $1,533,100 worth of shares (4,627 units at $331.34), decreasing direct ownership by 11% to 22,129 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. converted options into 1,908 shares, increasing direct ownership by 3% to 61,710 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga converted options into 1,666 shares, increasing direct ownership by 5% to 33,435 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 158 shares, increasing direct ownership by 0.74% to 21,422 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal was granted 4,579 shares and sold $695,201 worth of shares (2,242 units at $310.08), increasing direct ownership by 10% to 24,848 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne sold $2,157,542 worth of shares (6,958 units at $310.08) and was granted 14,209 shares, increasing direct ownership by 9% to 85,662 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga was granted 4,000 shares and sold $607,448 worth of shares (1,959 units at $310.08), increasing direct ownership by 7% to 31,769 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 4,000 shares and sold $1,284,980 worth of shares (4,000 units at $321.24) (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. was granted 4,579 shares and sold $695,201 worth of shares (2,242 units at $310.08), increasing direct ownership by 4% to 59,802 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal sold $547,929 worth of shares (1,510 units at $362.87) and was granted 3,800 shares, increasing direct ownership by 11% to 22,511 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne sold $3,475,157 worth of shares (9,577 units at $362.86) and was granted 19,003 shares, increasing direct ownership by 14% to 78,411 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. was granted 6,193 shares and sold $1,008,766 worth of shares (2,780 units at $362.87), increasing direct ownership by 6% to 57,465 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga was granted 3,800 shares and sold $547,927 worth of shares (1,510 units at $362.87), increasing direct ownership by 8% to 29,728 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 3,800 shares and sold $1,395,992 worth of shares (3,800 units at $367.37) (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 4 filed by Director Arbuckle Stuart A4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 3 filed by new insider Arbuckle Stuart A3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne exercised 4,697 shares at a strike of $106.40 and covered exercise/tax liability with 1,121 shares, increasing direct ownership by 5% to 68,985 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph exercised 8,161 shares at a strike of $119.13 and sold $5,483,990 worth of shares (12,128 units at $452.18), decreasing direct ownership by 16% to 21,264 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne exercised 25,650 shares at a strike of $117.18 and sold $11,613,003 worth of shares (25,650 units at $452.75) (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, CLO and Secretary Supran Bryan was granted 13,026 shares (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. was granted 7,752 shares and sold $1,727,284 worth of shares (3,821 units at $452.05), increasing direct ownership by 8% to 54,052 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne was granted 18,112 shares and sold $4,034,085 worth of shares (8,924 units at $452.05), increasing direct ownership by 16% to 65,409 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga was granted 2,851 shares and sold $635,126 worth of shares (1,405 units at $452.05), increasing direct ownership by 6% to 27,438 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 4,953 shares and sold $1,103,451 worth of shares (2,441 units at $452.05), increasing direct ownership by 11% to 25,231 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal was granted 5,959 shares and sold $2,692,062 worth of shares (5,959 units at $451.76) (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SEC Form 3 filed by new insider Supran Bryan3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Director Reitan Colleen F exercised 18,000 shares at a strike of $100.65 and sold $8,416,730 worth of shares (18,000 units at $467.60) (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga sold $1,557,649 worth of shares (3,474 units at $448.37), decreasing direct ownership by 12% to 25,992 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP Chief R&D Garg Pushkal was granted 2,851 shares and sold $1,299,746 worth of shares (2,851 units at $455.89) (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Commercial Officer Tanguler Tolga was granted 2,851 shares and sold $632,759 worth of shares (1,396 units at $453.27), increasing direct ownership by 5% to 29,466 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- EVP, Chief Financial Officer Poulton Jeffrey V. was granted 4,644 shares and sold $1,030,727 worth of shares (2,274 units at $453.27), increasing direct ownership by 5% to 50,121 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Chief Executive Officer Greenstreet Yvonne was granted 14,252 shares and sold $3,163,346 worth of shares (6,979 units at $453.27), increasing direct ownership by 15% to 56,221 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 2,851 shares and sold $632,759 worth of shares (1,396 units at $453.27), increasing direct ownership by 7% to 22,719 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)